NASDAQ:ABUS
Arbutus Biopharma Corporation Stock News
$2.73
+0.0100 (+0.368%)
At Close: Apr 26, 2024
Global Gene Therapy Market Projected to Grow with a CAGR of 34.8% During the Forecast Period, 2019-2026 - ResearchAndMarkets.com
03:48pm, Tuesday, 25'th Feb 2020
The "Gene Therapy Market by Vector Type, Gene Type and Application: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.
PLUG, Z among premarket gainers
02:17pm, Thursday, 20'th Feb 2020
Brickell Biotech (NASDAQ:BBI) +64% on positive sofpironium bromide data.Adesto Technologies (NASDAQ:IOTS) +55% on being acquired by Dialog Semiconductor.Stamps.com (NASDAQ:STMP) +39% on Q4 results.
Investment Analysts' New Coverage for February, 19th (ABUS, AEE, AEP, CNP, D, ES, ETR, EXC, ITCI, NEE)
11:28pm, Wednesday, 19'th Feb 2020
Investment Analysts’ new coverage for Wednesday, February 19th: Robert W. Baird initiated coverage on shares of Arbutus Biopharma (NASDAQ:ABUS). The firm issued an outperform rating on the stock. BM
Stock Charts To Watch - Wednesday, February 5
02:00am, Thursday, 06'th Feb 2020
Puma Biotechnology, Inc. exploded Wednesday, jumping 3.98 or 38%, to 14.56, after reaching a high of 15.00, on a whopping 23 million shares traded.
6 Biotechnology Stocks Moving In Wednesday's Pre-Market Session
12:42pm, Wednesday, 05'th Feb 2020
Gainers
• Moleculin Biotech, Inc. (NASDAQ:MBRX) stock rose 35.2% to $1.19 during Wednesday's pre-market session.
• Arbutus Biopharma, Inc. (NASDAQ:ABUS) shares rose...
Arbutus Biopharma (NASDAQ:ABUS) and GlycoMimetics (NASDAQ:GLYC) Head-To-Head Contrast
06:46am, Friday, 17'th Jan 2020
Arbutus Biopharma (NASDAQ:ABUS) and GlycoMimetics (NASDAQ:GLYC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of th
The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO
11:31am, Thursday, 10'th Oct 2019
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct.
